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ABSTRACT 
The objective of the present study was to study the effect of polymers on sustained release of Captopril from tablets. Compatibility was studied 
by Fourier transform infrared spectroscopy and DSC. The tablets were prepared by direct compression technique using Xanthan g um and Ethyl 
Cellulose. The prepared matrix tablets were evaluated for their physicochemical parameters such as weight variation, hardness, friability, 
content uniformity and in-vitro dissolution. Pre and post compression parameters were evaluated and all the parameters were found within the 
limit. The drug release data were subjected to different models in order to evaluate release kinetics and mechanism of drug release. 
Formulation F4 was selected as best formulation. The dissolution of formulation F4 can be Shows Non-fickian drug release mechanism. 
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INTRODUCTION  
Sustained release technology is relatively new field and as a 
consequence, research in the field has been extremely fertile 
and has produced many discoveries. With many drugs, the 
basic goal is to achieve a steady state blood level that is 
therapeutically effective and non-toxic for an extended 
period of time. The design of proper dosage form is an 
important element to accomplish this goal. Sustained 
release, sustained action, prolonged action, controlled 
release, extended action, timed release and depot dosage 
form are term used to identify drug delivery system that are 
designed to achieve prolonged therapeutic effect by 
continuously releasing medication over an extended period 
of time after administration of a single dose. In the case of 
oral sustained released dosage form, an effect is for several 
hours depending upon residence time of formulation in the 
GIT. The success of a therapy depends on selection of the 
appropriate delivery system as much as drug itself.1 
Sustained release dosage forms are designed to complement 
pharmaceutical activity of the medication in order to achieve 
better selectivity and longer duration of action. Captopril 
belongs to class Angiotensin Converting Enzyme inhibitor 
(ACE inhibitor). It effects the rennin-Angiotensin system and 
inhibits the conversion of relatively inactive Angiotensin I to 
active Angiotensin II. Thus, ACE inhibitors attenuate or 
abolish responses to Angiotensin I but not to Angiotensin II. 
Hence the inhibition of ACE therefore may induce the effect 
unrelated to reducing the level of Angiotensin II. ACE 
inhibition increase bradykinin synthesis which stimulate 
prostaglandin biosynthesis. Bradykinin and prostaglandin 
contribute pharmacological effect of ACE inhibitor. All these 
effects produce pharmacological actions like vasodilatation 
etc which ultimately decrease the blood pressure. Captopril 
is freely water-soluble and has a half-life 1.9 hours. It is 
usually prescribed to patients who are chronically ill and 
require long term use for therapeutic benefits. Development 
of a captopril oral formulation would be a significant 
advantage for patient compliance accompanied by 
minimization of the drug side effects as a result of reduction 
in the drug blood concentration fluctuations, especially in 
long-term therapy. The aim of this study was to prepare 
matrix tablets of Captopril using varying proportions of the 
Xanthan gum and Ethyl cellulose. 
MATERIALS & METHODS 
MATERIALS 
Captopril was purchased from Swapnroop Drugs and 
Pharmaceuticals (Aurangabad, India)., HPMC K 100,Xanthan 
gum, PVP K30 purchased from Balaji Drugs, Ethyl cellulose, 
Lactose are from Modern Industries (Malegaon), and 
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Magnesium stearate , Talc are from Research lab fine chem 
industries (Mumbai). 
METHOD OF PREPARATION OF MATRIX TABLETS 
Matrix tablets of Captopril were prepared by direct 
compression technique using varying proportions of 
polymers in combination. The composition of matrix tablets 
is given in table -1. All the ingredients were individually 
passed through a 60 mesh sieve, except glidant and 
lubricant. For each formulation required quantities of 
Captopril, polymer (xanthan gum and Ethyl Cellulose), were 
accurately weighed according to the composition and mixed 
in a polybag for about 30 to 45 minutes. The obtained blend 
was lubricated with talc and magnesium stearate for another 
5 minutes. The appropriate amount of the mixture was 
weighed and then compressed using 8 station rotary tablet 
press (CEMACH machineries ltd Ahmedabad, India) 
equipped with 11 mm flat faced punches at a constant 
compression force required to produce hardness of tablets 
about 2-4 kg/ cm2. All the tablets were stored in airtight 
containers for further use. 
  
Table 1: Formulation code for each Batch 
Sr.no. Excipients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Drug 25 25 25 25 25 25 25 25 25 
2 HPMC     K-100 30 30 30 30 30 30 30 30 30 
3 Xanthan gum 30 30 30 40 40 40 50 50 50 
4 Ethyl cellulose 30 40 50 30 40 50 30 40 50 
5 PVP 15 15 15 15 15 15 15 15 15 
6 Lactose 54 44 34 44 34 24 34 24 14 
7 Magnesium stearate 6 6 6 6 6 6 6 6 6 
8 Talc 10 10 10 10 10 10 10 10 10 
9 Total weight 200 200 200 200 200 200 200 200 200 
 
 
PRE-COMPRESSION PARAMETERS 
Angle of repose () 
Angle of repose is defined as the maximum angle possible 
between the surface of a pile of the powder and horizontal 
plane. The frictional force in a loose powder or granules can 
be measured by the angle of repose. 
                                                       tan= h / r 
 = tan-1 (h/r) 
    Where, is the angle of repose 
 h is height of pile  
 r is radius of the base of the pile    
Carr’s compressibility index 
The compressibility index of the granules was determined 
by the Carr’s compressibility index. (%) Carr’s Index can be 
calculated by using the following formula 
Carr’s Index (%) = 
TBD
 LBD - TBD
x 100 
POST-COMPRESSION PARAMETERS 
The prepared matrix tablets were evaluated for their 
physical properties like , hardness and friability, swelling 
index and drug content. 
Hardness test 
Tablets require a certain amount of strength, or hardness 
and resistance to friability, to withstand mechanical shocks 
of handling during manufacture, packaging and shipping. 
The hardness of the tablets was determined using Digital 
Hardness tester. It is expressed in Kg/cm2. Three tablets 
were randomly picked from each formulation and the mean 
and standard deviation values were calculated. 
 
 
Friability test 
It is the phenomenon whereby tablet surfaces are damaged 
and/or show evidence of   lamination or breakage when 
subjected to mechanical shock or attrition.  
The friability of tablets was determined by using Electro lab, 
USP EF 2 friabilator. It is expressed in percentage (%). Ten 
tablets were initially weighed (Winitial) and transferred into 
friabilator. The friabilator was operated at 25 RPM for 4 
minutes. The tablets were weighed again (Wfinal). The 
percentage friability was then calculated by, 
F =    100x
W
   W-  W
 initial
finalinitial  
% Friability of tablets less than 1% is considered acceptable.  
Swelling index  
Swelling of tablet involves the absorption of a liquid 
resulting in an increase in weight and volume. Liquid uptake 
by the particle may be due to saturation of capillary spaces 
within the particles or hydration of macromolecule. The 
liquid enters the particles or hydration of macromolecules. 
The liquid enters the particles through pores and bind to 
large molecule; breaking the hydrogen bond and resulting in 
the swelling of particle .The extent of swelling can be 
measured in terms of %weight gain by the tablet. The 
swelling index of tablets was determined in 0.1 N HCl (pH 
1.2) at room temperature. After each interval the tablet was 
removed from beaker, remove the excess buffer by using 
filter paper and weighed again upto 8 hrs.  
The swelling index was calculated by the following equation: 
 Swelling index (SI) = (Wt – W0)/WO × 100  
Where, Wt= Weight of tablet at time t.  
W0 = Initial weight of tablet 
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Drug content 
Take the powder of 20 tablets. Weighed a quantity of 
powder containing 0.1gm of Captopril with 150ml of 
phosphate buffer pH6.8 for 10 minutes, add sufficient 
phosphate buffer pH6.8 to produce 200ml and filter. Dilute 
10 ml of filtrate to 100ml with water and measure the 
absorbance at 233nm. 
In vitro dissolution study 
In vitro drug release studies of matrix tablets were done in 
eight-station USP XXII type II dissolution test apparatus( 
Electro lab TDT-08, India) at 37°C (± 0.5°C) and 50 rpm 
speed in 900 mL of dissolution medium. Dissolution medium 
consisted of 0.1N hydrochloric acid for the first 2 hours and 
phosphate buffer pH 6.8 from 3 to 8 hours. Five millitre 
(5ml) samples were taken by filtration at predetermined 
time intervals and after each sampling the volume of 
dissolution medium was replaced with 5ml of phosphate 
buffer (pH 6.8) .The amount of drug released is determined 
spectrophotometrically 
In- Vitro Drug Release Kinetic Study 
Zero Order Kinetics 
A Zero order release would be predicted by the following 
equation, 
Qt-Q0=K0t 
Where 
Qt =Amount of drug release dissolved in time ‘t’ 
Co=Initial amount of drug concentration in solution. 
Kot=Zero order rate constant. 
When the data were plotted as cumulative % drug release 
versus time, if the plot is linear then data obeys zero order 
kinetics with slope equal to K0. This model represents an 
ideal release profile in order to achieve the prolonged 
pharmacological action. 
First Order Kinetics: 
A first order release would be predicted by the following 
equation 
Log Qt=Log Q0-Klt/2.303 
Where, 
Qt=Amount of drug released in time ‘t’ 
Co=Initial amount of drug concentration in solution. 
Klt=first order rate constant 
When data were plotted as log cumulative% drug remaining 
versus time yields a straight line indicating that the release 
follows first order kinetics. The constant K can be obtained 
multiplying slope values.   
Higuchi’s Model:  
Drug release from the matrix device by diffusion has been 
described by Higuchi’s diffusion equation 
Ft=Q=VD5/T(2C-5Cs)Cst 
Where, 
Q=Amount of drug release dissolved in time ‘t’. 
Co=diffusion coefficient of drug in the release matrix. 
Cs=Solubility of drug in the matrix. 
5=porosity of matrix 
t=Tortuosity 
T=Time (h) 
The equation may be simplified then the equation becomes, 
Ft=Q=KhX t1/2 
Where, 
Kh=Higuchi dissolution constant 
When data were plotted according to this equation, i.e. 
cumulative drug released versus square root of time, yields a 
straight line, indicating that the drug was released by 
diffusion mechanism. 
 
Peppas Korsmeyer Equation 
In 1983 korsmeyer et.al  developed a simple, semiempirical 
model, when diffusion is the main drug release mechanism, 
relating exponentially the drug release to the elapsed time 
(t) 
At/Ao=Kt/n 
Where, 
K=Constant 
n=Release 
t=Time 
At and Ao=Absolute cumulative amount of drug released at 
times. 
This is used when the release mechanism is not well known 
or when more than one type of a release phenomenon could 
be involved. 
RESULTS AND DISCUSSION 
Precompression parameters: 
The powder mixture of all the formulations were evaluated 
for angle of repose, bulk density, tapped density, 
compressibility index and their values were shown in table 
2. The bulk density  0.36 to 52 g/ml and  Powder blend 
indicated good flow properties with an angle of repose 
values ranging from 22.56to 31.44. The compressibility 
index for all the formulations were found to be less than 22 
%, which indicates that the powder mixture has good flow 
properties. Hausner’s ratio was also calculated, the ration 
was ranged between 1.07 and 1.28. 
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Precompression parameters  
Table 2: Precompression parameters for sustained release matrix tablets of captopril F1 to F9 
Formulation code 
Angle of 
repose(0) 
Bulk density 
(g/ml) 
Tapped density 
(g/ml) 
Carr’s index (%) Hausner’s ratio 
F1 31.44±0.14 0.42±0.07 0.54±0.10 22.22±0.1 1.28±0.1 
F2 24.72±0.2 0.39±0.110 0.42±0.9 7.14±0.2 1.07±0.4 
F3 27.58±0.9 0.36±0.096 0.41±0.69 12.19±0.1 1.13±0.1 
F4 28.73±0.2 0.52±0.135 0.59±0.2 11.86±0.3 1.13±0.1 
F5 25.52±0.4 0.50±0.108 0.63±0.2 20.63±0.2 1.26±0.1 
F6 23.85±0.1 0.37±0.160 0.45±0.2 17.77±0.1 1.21±0.1 
F7 30.24±0.4 0.48±0.195 0.56±0.1 14.28±0.1 1.16±0.1 
F8 22.56±0.4 0.42±0.17 0.52±0.18 19.23±0.1 1.23±0.2 
F9 31.68±0.5 0.44±0.145 0.56±0.13 21.42±0.2 1.27±0.1 
 
Evaluation of postcompression parameters 
Sustained release matrix tablets of Captopril were prepared 
by direct compression technique. Total nine formulations 
were prepared. The tablet weight variation, hardness, 
friability and content uniformity for each formulation are 
shown in table 3. The weight variation test indicated that the 
percentage deviation of all tablet formulations was found to 
be within pharmacopoeial acceptable limit. The hardness of 
all the tablets was within  the range of 2.8±3.9kg/cm. The 
drug content in all the batches was determined by 
measuring absorbance of sample at 233 nm using double 
beam UV spectrophotometer (LABINDIA). The content 
uniformity among different formulations was found to be 
higher and the drug content in the range of 82.23 to 90.75% 
which indicates uniform drug distribution in all the 
formulations. 
Post compression parameters  
 
Table 3: Post compression parameters for sustained release matrix tablets of captopril  F1 to F9 
Formulation code  Hardness  Thickness  Friability  Weight variation  
F1 3.3±0. 20 2.84±0.02 0.67±0.02 200.0±0.17 
F2 3.2±0.05 2.8±0.04 0.50±0.12 200.8±1.06 
F3 2.9±0.05 2.83±0.08 0.63±0.05 201.5±0.63 
F4 3.9±0.23 2.82±0.15 0.72±1.35 201.0±1.25 
F5 2.9±0.11 2.70±0.07 0.59±0.13 200.3±0.86 
F6 3.2±0.15 2.68±0.19 0.82±0.01 200.4±0.44 
F7 3.1±0.25 2.74±0.21 0.68±0.16 200.4±0.69 
F8 2.8±0.11 2.77±0.06 0.59±0.10 200.3±0.73 
F9 3.3±0.45 2.80±0.26 0.67±0.17 200.8±0.68 
 
Swelling Index 
The swelling behavior of a dosage unit was measured by 
studying its weight gain. The swelling index of tablets was 
determine by placing the tablets in a petridish using 
dissolution medium as 0.1N HCL(pH 1.2) and pH 7.4 
phosphate buffer. After 1, 2, 4, 6, and 8 hours. Each tablet 
was withdrawn carefully, blotted with tissue paper to 
remove for each time interval. 
 
Table 4. Swelling index of formulations (F1-F9) 
Sr.no Time F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 0 0 0 0 0 0 0 0 0 0 
2 47 58 28 58.2 47 48.4 38.2 49.2 62.1 47 
3 57.56 63.5 34.65 69 49 51 42.01 52.2 66.5 57.56 
4 67.4 74.5 45.54 76.5 53.5 61.5 50.5 65.1 74.1 67.4 
5 75.5 86.1 56.1 94.5 65.5 74.1 62.5 80.5 88.2 75.5 
6 92.2 98.2 64.3 102 79 84.5 68 92.5 98.5 92.2 
7 104.5 107.5 72.3 114 90.5 92.5 74.5 101.2 103.2 104.5 
8 111.3 118.2 85.5 125.5 103.5 110.1 91.59 118.5 114.3 111.3 
9 119.2 124.5 96.2 131.7 107.5 115.5 99.01 125.5 127.5 119.2 
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Figure 1.Swelling index of Captopril  SR Matrix tablet 
In vitro dissolution study 
Captopril release from the matrix tablets was studied for 
first two hours in 0.1 n HCL and the next six hours in pH 6.8 
phosphate buffer. Total nine formulations were made with 
Xanthan gum and Ethyl Cellulose with different ratios. In 
batch F1, F2, & F3 Xanthan gum & Ethyl cellulose was used 
as a sustained release polymers. Preformulation study & 
Physicochemical evaluation of matrix tablets was conducted 
and results are shown in table 18 & 19.In vitro dissolution 
study results of F1 showed 59.57% drug release within 8 
hrs. F2 showed 60.31% & F3 showed 64.73% cumulative 
drug release in 8 hrs. Thus sustained release profile was not 
achieved. So in next batch F4 it was decided to increase the 
amount of xanthan gum. In batch F4 amount of xanthan gum 
was increased as compared to used in batch F1, F2 & F3. 
Results obtained of dissolution study showed 90.75% 
cumulative drug release within 8 hrs. which is in compliance 
with desired drug release profile. It happened due to the 
increase amount of xanthan gum. Xanthan gum used to 
produce directly compressed matrices that display a high 
degree of swelling due to water uptake and hence it gives 
desired results. 
 In Batch F5, F6, F7, F8, F9 xanthan gum & ethyl cellulose 
was used in different ratios. In vitro dissolution study 
showed 71. 05 %, 80.21 % , 85.78%, 93.47% & 88.42% 
cumulative drug release in 8 hrs.These results indicated that 
the Xanthan gum could control the release of Captopril up to 
8 hr when it combined with Ethyl Cellulose. 
 
 
Fig.- 2: Comparative in-vitro dissolution profile of all the formulations  
 
KINETIC STUDY 
The classical zero order released curved was found to be 
linear the curve plotted according to first order and 
Highuchi and Conner’s were also found to be linear 
respectively. For the Korsemeyer’s Peppas released curves 
r2 was found to be ≥ 0.90 for all formulation and n value was 
found to be ≥ 0.5 which indicate that all  the formulation 
show anomalous or non-fickian diffusion. The drug release 
occurs probably by diffusion, erosion and dissolution 
follows. 
In the present study, the drug released mechanism from all 
Sustained release matrix tablet formulation different kinetic 
models was analyzed using factorial design batches followed 
zero order , first order kinetic, Highuchi model  and 
Korsemeyer’s Peppas model kinetics 
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Figure 3: Model graph for comparative evaluation of zero order release kinetics 
 
 
Figure 4: Model graph for comparative evaluation of first order release kinetics 
 
 
Figure 5: Model graph for comparative evaluation of Higuchi order release kinetics 
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Figure 6: Model graph for comparative evaluation of krosemayers peppas 
Table 5: Correlation coefficients according to the different kinetic equations used for describing Captopril release 
behavior from sustained release matrix tablets. 
Formulation 
code  
Zero order First order Higuchi 
Model 
Krosmeyer 
peppas 
F1 0.961 0.515 0.910 0.927 
F2 0.952 0.463 0.872 0.947 
F3 0.964 0.458 0.921 0.921 
F4 0.963 0.434 0.907 0.941 
F5 0.963 0.511 0.918 0.931 
F6 0.962 0.489 0.918 0.929 
F7 0.960 0.552 0.914 0.941 
F8 0.953 0.530 0.912 0.942 
F9 0.949 0.027 0.926 0.901 
 
DRUG EXCIPIENT COMPATIBILITY STUDY 
Infrared spectrophotometer is a useful analytical technique 
utilized to check the chemical interaction between the drug 
and the other excipients used in the formulation. The sample 
1mg was powdered and mixed with the 10mg of dry 
powdered potassium bromide. The powdered mixture was 
taken in a sampler and the spectrum was recorded by 
scanning in the wavelength region of 4000-400 cm-1 using 
FTIR spectrophotometer. 
Fourier transform infra red spectroscopy studies revealed 
that pure Captopril showed typical bands at 1734.06 cm–1 
due to C=O  stretching of carboxylic group  and a band at 
1690 cm–1 due to C=O s stretching of amide group ,C-H 
stretching at a 2970 cm -1  and C-C stretching at  cm–1 .No 
significant shifts of reduction in intensity of the FTIR bands 
of Captopril  were observed as shown in figure 7 a). From 
the FTIR spectra shown in fig 7 b), it is very clear that there 
are no interactions between drug and excipients. 
  
 
Fig.- 7 a) : FTIR spectra of pure Captopril 
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Figure- 7 b) : FTIR spectra of Captopril + Xanthan gum 
 
Differential Scanning Calorimetry: 
Thermal analysis of drug was carried out using DSC. The DSC curve of captopril profile a sharp exothermic peak at 108 0C 
corresponding to its melting, and indicating its crystalline nature and purity of sample.  The DSC thermogram is shown in figure. 
 
Figure 8: DSC Thermogram of Captopril 
 
CONCLUSION 
Sustained release matrix tablets of Captopril were prepared 
using different ratios of xanthan gum and   Ethyl cellulose by 
direct compression method. The results of the present study 
demonstrates that the xanthan gum and Ethyl Cellulose 
control the Captopril release effectively for 8 hrs,. It is 
concluded that sustained release of Captopril over a period 
of 8 hours was obtained with formulation (F-4) containing 
high amount of Xanthan gum and Ethyl cellulose. Sustained 
release matrix tablets of Captopril can be expected to reduce 
the frequency of administration and decrease the dose 
dependent side effects associated with repeated 
administration of conventional Captopril tablets. 
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